source
- Summit slips on ivonescimab's apparent interim miss in sign of investor frustrationSummit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonesci…Endpoints · 2mo ago↗ source
- Amgen files update to Tavneos label as FDA escalates push to withdrawAmgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would add more information to the warning ...Endpoints · 2mo ago↗ source
- Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debutA trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined. Seaport Therapeutics, Hemab Therapeutic…